Treatment of Allergic Rhinitis as a Strategy for Preventing Asthma
- 341 Downloads
Purpose of Review
To evaluate the impact of allergic rhinitis (AR) on the development of asthma and to update readers on recent literature suggesting that early treatment of allergic subjects with immunotherapy may prevent asthma onset.
AR is frequently associated with asthma, leading to the concept that these two conditions are different aspects of the same disease. There is increasing evidence that AR precedes the onset of asthmatic symptoms and current treatment strategies are beneficial in symptom control with no impact prevention. There is limited knowledge about the risk factors responsible for the progression of AR to asthma, though recent data supports the notion that it is possible to prevent asthma onset by allergen immunotherapy.
Despite significant advances in specific immunotherapy (SIT) therapy strengthening its efficacy in AR and possible prevention of progression to asthma, the adoption of this therapeutic strategy is still restricted in comparison to therapies directed towards treatment of AR symptoms. Unlike corticosteroids and other symptomatic therapies, the benefit of SIT treatment in allergic individuals has been shown to prevent the development of allergic conditions. Hence, large well-conducted randomized clinical trials with long-term efficacy of SIT are required to confirm or refute the concept that SIT may abrogate the progression of AR to asthma in patients.
KeywordsAllergic rhinitis Asthma Specific immunotherapy SIT Prevention
Compliance with Ethical Standards
Conflict of Interest
Dr. Morjaria reports non-financial support from Boehringer Ingelheim, during the conduct of the study; personal fees and other from Boehringer Ingelehim; Chiesi; AstraZeneca; Novartis; Teva UK Ltd; Pfizer; and GlaxoSmithKline, outside the submitted work. The other authors declare no conflicts of interest relevant to this manuscript.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Bro JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision. 2017.Google Scholar
- 4.•• Giavina-Bianchi P, Aun MV, Takejima P, Kalil J, Agondi RC. United airway disease: current perspectives. J Asthma Allergy. 2016;9:93–100. This paper gathers epidemiologic, pathophysiologic, and clinical evidence for an integrated view of rhinitis and asthma defining them unitarily as “united airway disease. CrossRefPubMedPubMedCentralGoogle Scholar
- 19.• Cirillo I, Ricciardolo FLM, Medusei G, Signori A, Ciprandi G. Exhaled nitric oxide may predict bronchial hyperreactivity in patients with allergic rhinitis. Int Arch Allergy Immunol. 2013;160(3):322–8. This study highlights the relevance of FeNO as a possible predictive marker for BHR in AR patients and underlines the close link between upper and lower airways. CrossRefPubMedGoogle Scholar
- 23.Asher MI, Montefort S, Björkstén B, Lai CKW, Strachan DP, Weiland SK, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet (Lond Engl). 2006;368(9537):733–43.CrossRefGoogle Scholar
- 30.• Aguilar D, Pinart M, Koppelman GH, Saeys Y, Nawijn MC, Postma DS, et al. Computational analysis of multimorbidity between asthma, eczema and rhinitis. PLoS One. 2017;12(6):e0179125. This in silico study highlights the molecular mechanisms overlap among AR and asthma. CrossRefPubMedPubMedCentralGoogle Scholar
- 31.BioCarta_Pathways [Internet]. [cited2017Nov 2]. Available from:https://cgap.nci.nih.gov/Pathways/BioCarta_Pathways.
- 39.Meadows A, Kaambwa B, Novielli N, Huissoon A, Fry-Smith A, Meads C, et al. A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis. Health Technol Assess. 2013;17(27):vi. xi–xiv, 1-322CrossRefPubMedPubMedCentralGoogle Scholar
- 48.Geier DA, Kern JK, Geier MR. Demographic and neonatal risk factors for childhood asthma in the USA. J Matern Fetal Neonatal Med. 2017:1–5.Google Scholar
- 49.O’Connor GT, Lynch SV., Bloomberg GR, Kattan M, Wood RA, Gergen PJ, et al. Early-life home environment and risk of asthma among inner-city children. Allergy Clin Immunol. 2017. https://doi.org/10.1016/j.jaci.2017.06.040.
- 50.Ferrini M, Carvalho S, Cho YH, Postma B, Miranda Marques L, Pinkerton K, et al. Prenatal tobacco smoke exposure predisposes offspring mice to exacerbated allergic airway inflammation associated with altered innate effector function. Part Fibre Toxicol. 2017;14(1):30.CrossRefPubMedPubMedCentralGoogle Scholar
- 68.Burks AW, Calderon MA, Casale T, Cox L, Demoly P, Jutel M, et al. Update on allergy immunotherapy: American academy of allergy, asthma & immunology/European academy of allergy and clinical immunology/PRACTALL consensus report. J Allergy Clin Immunol. 2013;131(5):1288–1296.e3.CrossRefPubMedGoogle Scholar
- 80.• Karakoc-Aydiner E, Eifan A, Baris S, Gunay E, Akturk H, Akkoc T, et al. Long-term effect of sublingual and subcutaneous immunotherapy in dust mite–allergic children with asthma/rhinitis: a 3-year prospective randomized controlled trial. J Investig Allergol Clin Immunol. 2015;25(255):334–42. This Randomized Controlled Trial shows the efficacy and the prevention effect of SIT in Dust Mite allergic children with AR or mild asthma. PubMedGoogle Scholar
- 81.Valovirta E, Petersen TH, Piotrowska T, Laursen MK, Andersen JS, Sørensen HF, et al. Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. J Allergy Clin Immunol. 2018;141(2):529-538. https://doi.org/10.1016/j.jaci.2017.06.014.CrossRefPubMedGoogle Scholar
- 82.British Thoracic Society and Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. 2016. Available from: https://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-guideline-2016/.
- 85.• Kristiansen M, Dhami S, Netuveli G, Halken S, Muraro A, Roberts G, et al. Allergen immunotherapy for the prevention of allergy: a systematic review and meta-analysis. Pediatr Allergy Immunol. 2017;28(1):18–29. This systematic review provides evidences of a reduced short-term risk of developing asthma in allergic rhinitis subjects treated with SIT. CrossRefPubMedGoogle Scholar
- 87.Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2003;4:CD001186.Google Scholar